MDT

89.67

-0.33%↓

VEEV

282.32

+2.35%↑

A

120.08

-2.61%↓

WBA

11.51

0%↓

HQY

97.34

+3.06%↑

MDT

89.67

-0.33%↓

VEEV

282.32

+2.35%↑

A

120.08

-2.61%↓

WBA

11.51

0%↓

HQY

97.34

+3.06%↑

MDT

89.67

-0.33%↓

VEEV

282.32

+2.35%↑

A

120.08

-2.61%↓

WBA

11.51

0%↓

HQY

97.34

+3.06%↑

MDT

89.67

-0.33%↓

VEEV

282.32

+2.35%↑

A

120.08

-2.61%↓

WBA

11.51

0%↓

HQY

97.34

+3.06%↑

MDT

89.67

-0.33%↓

VEEV

282.32

+2.35%↑

A

120.08

-2.61%↓

WBA

11.51

0%↓

HQY

97.34

+3.06%↑

Search

Crinetics Pharmaceuticals Inc

Fermé

SecteurSoins de santé

32.88 3.56

Résumé

Variation du prix de l'action

24h

Actuel

Min

31.93

Max

33.23

Chiffres clés

By Trading Economics

Revenu

-16M

-97M

Ventes

361K

361K

Marge bénéficiaire

-26,807.202

Employés

437

EBITDA

-17M

-110M

Recommandations

By TipRanks

Recommandations

Achat Fort

Prévisions sur 12 Mois

+127.59% upside

Dividendes

By Dow Jones

Prochains Résultats

7 août 2025

Statistiques du Marché

By TradingEconomics

Capitalisation Boursière

-369M

2.8B

Ouverture précédente

29.32

Clôture précédente

32.88

Sentiment de l'Actualité

By Acuity

89%

11%

357 / 376 Classement par Healthcare

Score Technique

By Trading Central

Confiance

Weak Bullish Evidence

Crinetics Pharmaceuticals Inc Graphique

Les performances passées ne sont pas un indicateur fiable des résultats futurs.

Actualités Associées

14 juil. 2025, 22:07 UTC

Principaux Mouvements du Marché

Trade Desk Rises on S&P 500 Inclusion

14 juil. 2025, 17:06 UTC

Principaux Mouvements du Marché

Crypto Assets Rally Ahead of Possible U.S. Legislation

14 juil. 2025, 16:47 UTC

Acquisitions, Fusions, Rachats

NatWest to Sell Stake in Permanent TSB

14 juil. 2025, 23:46 UTC

Market Talk

Nikkei May Rise as Yen Weakens -- Market Talk

14 juil. 2025, 23:38 UTC

Market Talk

Gold Edges Higher Ahead of U.S. CPI Data -- Market Talk

14 juil. 2025, 23:37 UTC

Market Talk

ANZ's Institutional Earnings Likely to Weigh on Outlook -- Market Talk

14 juil. 2025, 23:29 UTC

Market Talk

South32 Bull Eyes Possible Last-Minute Power Deal for Mozal -- Market Talk

14 juil. 2025, 23:29 UTC

Market Talk

Global Energy Roundup: Market Talk

14 juil. 2025, 23:02 UTC

Résultats

China Vanke: Additional Provision for Asset Impairment Also Among Factors Weighing on Results >000002.SZ

14 juil. 2025, 23:02 UTC

Résultats

China Vanke: Weakness in Overall China Real-Estate Sector Weighed on Results >000002.SZ

14 juil. 2025, 23:02 UTC

Résultats

China Vanke 1H Loss Was CNY9.85B >000002.SZ

14 juil. 2025, 23:01 UTC

Résultats

China Vanke Sees 1H Loss CNY10.0B-Loss CNY12.0B >000002.SZ

14 juil. 2025, 23:01 UTC

Résultats

China Vanke Expects 1H Loss to Widen >000002.SZ

14 juil. 2025, 20:50 UTC

Market Talk

Tech, Media & Telecom Roundup: Market Talk

14 juil. 2025, 20:50 UTC

Market Talk

Basic Materials Roundup: Market Talk

14 juil. 2025, 20:07 UTC

Market Talk

Cloud Computing Giants Will Be the Winner from Software's Loss -- Market Talk

14 juil. 2025, 20:05 UTC

Market Talk

Adobe and Salesforce May Struggle to Keep Up With AI Agents -- Market Talk

14 juil. 2025, 19:11 UTC

Market Talk

Oil Retreats Despite Trump Threats of Russia Sanctions -- Market Talk

14 juil. 2025, 19:09 UTC

Market Talk

Gold Breaks a 3-Day Win Streak -- Market Talk

14 juil. 2025, 18:59 UTC

Market Talk

Hotter Weather Outlook, LNG Flows Boost U.S. Natural Gas -- Market Talk

14 juil. 2025, 18:30 UTC

Acquisitions, Fusions, Rachats

Synopsys Buy of Ansys Gets China OK. The $35 Billion Deal Is Set to Close. -- Barrons.com

14 juil. 2025, 18:25 UTC

Market Talk

Dollar Gains, Treasury Yields Lose Steam as Trump Threatens Russia -- Market Talk

14 juil. 2025, 18:25 UTC

Market Talk

Global Forex and Fixed Income Roundup: Market Talk

14 juil. 2025, 16:59 UTC

Market Talk

Goldman Sachs Lifts 2H25 Crude Price Views -- Market Talk

14 juil. 2025, 16:53 UTC

Actions en Tendance

Stocks to Watch Monday: Kenvue, Tesla, Synopsys, Robinhood -- WSJ

14 juil. 2025, 16:27 UTC

Market Talk

Oil Falls as Investors Monitor U.S.-EU Trade, Trump's Russia Sanction Threats -- Market Talk

14 juil. 2025, 16:20 UTC

Market Talk
Résultats

Auto & Transport Roundup: Market Talk

14 juil. 2025, 16:20 UTC

Market Talk

Basic Materials Roundup: Market Talk

14 juil. 2025, 16:15 UTC

Market Talk

Global Commodities Roundup: Market Talk

14 juil. 2025, 16:12 UTC

Market Talk
Acquisitions, Fusions, Rachats

Waters Closer to Thermo Fisher, Danaher With Becton Dickinson Unit -- Market Talk

Comparaison

Variation de prix

Crinetics Pharmaceuticals Inc prévision

Objectif de Prix

By TipRanks

127.59% hausse

Prévisions sur 12 Mois

Moyen 72.67 USD  127.59%

Haut 97 USD

Bas 36 USD

Basé sur 10 analystes de Wall Street proposant des objectifs de prix à 12 mois pour Microsoft Corp. au cours des 3 derniers mois.

Note du Consensus

By TipRanks

Achat Fort

10 ratings

9

Achat

1

Maintien

0

Vente

Score Technique

By Trading Central

30.39 / 33.46Support & Résistance

Court Terme

Weak Bullish Evidence

Moyen Terme

Bearish Evidence

Long Terme

Neutral Evidence

Sentiment

By Acuity

357 / 376Classement par Soins de santé

Sentiment de l'Actualité

Très Fortes Indications Baissières

Volatilité

Inférieur à la moyenne

Changement du Volume d'Actualités (RCV)

Supérieur à la moyenne

Éléments financiers

Frais Généraux et Administratifs

Dépenses d'exploitation

Résultat avant impôt

Ventes

Coût des ventes

Marge brute des ventes

Charges d'intérêt sur la dette

EBITDA

Bénéfice d'exploitation

$

À Propos Crinetics Pharmaceuticals Inc

Crinetics Pharmaceuticals, Inc., a clinical-stage pharmaceutical company, focuses on the discovery, development, and commercialization of novel therapeutics for rare endocrine diseases and endocrine-related tumors. The company's lead product candidate is paltusotine, an oral selective nonpeptide somatostatin receptor type 2 agonist, which is in Phase 3 trial for the treatment of acromegaly; and Phase 2 trial for treating carcinoid syndrome associated with neuroendocrine tumors. It is also developing CRN04894, an investigational oral nonpeptide product candidate to antagonize the adrenocorticotrophic hormone (ACTH) receptor that has completed a Phase 1 study for the treatment of diseases caused by excess ACTH, including congenital adrenal hyperplasia and Cushing's disease. In addition, the company is developing antagonists of the parathyroid hormone (PTH) receptor for the treatment of primary hyperparathyroidism and humoral hypercalcemia of malignancy, and other diseases of excess PTH; identified investigational orally available somatostatin receptor type 3 targeted nonpeptide agonists for the treatment of autosomal dominant polycystic kidney disease; and developing thyroid-stimulating hormone receptor antagonists for the treatment of graves' disease and thyroid eye disease, as well as Oral GLP-1 and GIP nonpeptides for the treatment of diabetes and obesity. Crinetics Pharmaceuticals, Inc. was incorporated in 2008 and is headquartered in San Diego, California.